Non-Viral Delivery of CRISPR/Cas Cargo to the Retina Using Nanoparticles: Current Possibilities, Challenges, and Limitations
Open accessThe DOI matches its Crossref record; 191 of the 192 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
The discovery of the CRISPR/Cas system and its development into a powerful genome engineering tool have revolutionized the field of molecular biology and generated excitement for its potential to treat a wide range of human diseases. As a gene therapy target, the retina offers many advantages over other tissues because of its surgical accessibility and relative immunity privilege due to its blood–retinal barrier. These features explain the large advances made in ocular gene therapy over the past decade, including the first in vivo clinical trial using CRISPR gene-editing reagents. Although viral vector-mediated therapeutic approaches have been successful, they have several shortcomings, including packaging constraints, pre-existing anti-capsid immunity and vector-induced immunogenicity, therapeutic potency and persistence, and potential genotoxicity. The use of nanomaterials in the delivery of therapeutic agents has revolutionized the way genetic materials are delivered to cells, tissues, and organs, and presents an appealing alternative to bypass the limitations of viral delivery systems. In this review, we explore the potential use of non-viral vectors as tools for gene therapy, exploring the latest advancements in nanotechnology in medicine and focusing on the nanoparticle-mediated delivery of CRIPSR genetic cargo to the retina.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This has created a need to explore alter native non-viral vector platforms for retinal gene therapy, such as liposome-based systems and synthetic nanoparticles (Salman et al., 2022).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Salman et al., 2022
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Folding DNA to create nanoscale shapes and patterns
Rothemund, P. W. K. (2006) · Nature · doi:10.1038/nature04586 · Cited by 7,354
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016) · Nature · doi:10.1038/nature17946 · Cited by 5,437
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Search-and-replace genome editing without double-strand breaks or donor DNA
Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1711-4 · Cited by 4,767
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Advances and Challenges of Liposome Assisted Drug Delivery
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00286 · Cited by 2,632
Cited by
Overview of Recent Advances in Nano-Based Ocular Drug Delivery
Liu, L.-C., Chen, Y., & Lu, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015352 · Cited by 174
Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy
Dubey, A. K., & Mostafavi, E. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1259435 · Cited by 103
In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications
Huang, K. L., Zapata, D. A., Tang, Y., Teng, Y., & Li, Y. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121876 · Cited by 66
Nanoplatform‐Based In Vivo Gene Delivery Systems for Cancer Therapy
Luo, R., Le, H., Wu, Q., & Gong, C. (2024) · Small · doi:10.1002/smll.202312153 · Cited by 53
Recent advances in carbon monoxide-releasing nanomaterials
Ning, X., Zhu, X., Wang, Y., & Yang, J. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.03.001 · Cited by 51
Castro, B. F. M., Steel, J. C., & Layton, C. J. (2023) · BioDrugs · doi:10.1007/s40259-023-00629-y · Cited by 42
Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?
Ail, D., Malki, H., Zin, E. A., & Dalkara, D. (2023) · The Application of Clinical Genetics · doi:10.2147/tacg.s383453 · Cited by 40
Bigini, F., Hyeon, L. S., Sun, Y. J., Sun, Y., & Mahajan, V. B. (2023) · Vision Research · doi:10.1016/j.visres.2023.108317 · Cited by 31
Future Perspectives of Prime Editing for the Treatment of Inherited Retinal Diseases
Hansen, S., McClements, M. E., Corydon, T. J., & MacLaren, R. E. (2023) · Cells · doi:10.3390/cells12030440 · Cited by 25
Self-citationPurdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
Self-citationRole of CRISPR/Cas9 in the treatment of Duchenne muscular dystrophy and its delivery strategies
Agrawal, P., Harish, V., Mohd, S., Singh, S. K., Tewari, D., Tatiparthi, R., Harshita, Vishwas, S., Sutrapu, S., Dua, K., et al. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122003 · Cited by 22
CRISPR delivery systems for organ-specific targeting: Advances and challenges
Du, J., Wu, Q., Liu, C., Wang, N., & Gong, C. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100048 · Cited by 21
Nanotechnology in Retinal Disease: Current Concepts and Future Directions
Mehta, N. J., & Mehta, S. N. (2023) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2023.0083 · Cited by 19
Cas-based bacterial detection: recent advances and perspectives
Lan, H., Shu, W., Jiang, D., Yu, L., & Xu, G. (2024) · The Analyst · doi:10.1039/d3an02120c · Cited by 16
Clinical and Therapeutic Evaluation of the Ten Most Prevalent CRB1 Mutations
da Costa, B. L., Kolesnikova, M., Levi, S. R., Cabral, T., Tsang, S. H., Maumenee, I. H., & Quinn, P. M. J. (2023) · Biomedicines · doi:10.3390/biomedicines11020385 · Cited by 15
Genetic therapies and potential therapeutic applications of CRISPR activators in the eye
Ng, B., Kaukonen, M. K., McClements, M. E., Shamsnajafabadi, H., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101289 · Cited by 14
Self-citationWang, B., Lu, J., Zhang, X., Hu, R., & Ma, H. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1669104 · Cited by 13
The effects of length and sequence of gRNA on Cas13b and Cas13d activity in vitro and in vivo
Liu, Y., Jing, P., Zhou, Y., Zhang, J., Shi, J., Zhang, M., Yang, H., & Fei, J. (2023) · Biotechnology Journal · doi:10.1002/biot.202300002 · Cited by 13
Shining light on CRISPR/Cas9 therapeutics for inherited retinal diseases
Geiger, A., Kennedy, J. G., Staker, L. G., Wensel, T. G., Casson, R. J., & Thomas, P. Q. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101376 · Cited by 11
CRISPR/Cas bioimaging: From whole body biodistribution to single-cell dynamics
Kolesova, E. P., Pulone, S., Kostyushev, D. S., & Tasciotti, E. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115619 · Cited by 10
Khodaei, R., Bayandori, M., Sarpoli, L. M. G., Souri, M., Hasanzade, I., Khodaee, R., Saeedi, S., Kiani, J., & Karimi, M. (2024) · Advances in Natural Sciences Nanoscience and Nanotechnology · doi:10.1088/2043-6262/ad6e5c · Cited by 8
Zeng, L., Wei, Y., Qiu, Y., Bi, R., Peng, H., Hu, B., & Li, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s521960 · Cited by 9
Non-viral gene therapy for Leber’s congenital amaurosis: progress and possibilities
Abdulsalam, L., Mordecai, J., & Ahmad, I. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2443387 · Cited by 7
Makhijani, S., Alasiri, G. A., Quadri, M. S. A., & Ingle, R. G. (2026) · Discover Nano · doi:10.1186/s11671-026-04653-z · Cited by 5
Salman, A., McClements, M. E., & MacLaren, R. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031697 · Cited by 5
Self-citationRecent Advances in the Non-viral Delivery of Genes to Central Nervous System Disorders
Marei, H. E. S. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01703-z · Cited by 4
Halagali, P., Seenivasan, R., Sreedevi, A., Ligade, V. S., Bugadannavar, P., Sharma, H., Nand, S., & Tippavajhala, V. K. (2026) · 3 Biotech · doi:10.1007/s13205-026-05016-2 · Cited by 5
CRISPR/Cas9-mediated Genome Editing: In vivo Review
Lotfalizadeh, N., Sadr, S., Simab, P. A., Hajjafari, A., Borji, H., & Bayat, Z. (2022) · Journal of Lab Animal Research · doi:10.58803/jlar.v1i1.13 · Cited by 4
CRISPR-Based Therapy for Ischemic Stroke: A Narrative Review
Alavian, F., & Ghasemi, S. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01662-x · Cited by 2
Unlocking non-model organisms with CRISPR-Cas: A roadmap for sustainable biotechnology
Sarsaiya, S., Jain, A., Chen, J., & Gong, Q. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108890 · Cited by 2
Modalities of vision restoration in optic neuropathies and retinal disease
Rubin, B. R., Lavinsky, F., Cain, R., Kuriyan, A. E., Wollstein, G., Zambrano, R., & Schuman, J. S. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101474 · Cited by 1
Lang, E., Tilton, J. C., & Sweet, T. J. (2024) · Columbia Undergraduate Science Journal · doi:10.52214/cusj.v17i1.10965
Mutation Specific Treatments for Inherited Retinal Diseases
Mercer, G., Ballios, B. G., & Kertes, P. J. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-72230-1_60
The Role of DNA in Neural Development and Cognitive Function
Raja, T. R. W., Udaiyappan, J. P., & Pillay, M. (2025) · DNA · doi:10.3390/dna5030037
Application of genetic scissoring in the management of genetically related diseases
Ogunlakin, A. D., Olusegun, O. V., Olusegun, S., Anejukwo, D. S., Asaleye, O., Balogun, H., Adedoyin, O. G., Ojo, O. A., Ogunlakin, O. A., & Sonibare, M. A. (2025) · Dietary Supplements and Nutraceuticals · doi:10.31989/dsn.v4i8.1730
Chou, S., Wang, C.-H., Chang, Y., Fang, W.-C., Hwang, D., Hsiao, Y., Luo, Y., Lo, W., Viet, N. Q., Tang, K.-Y., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148300
Development of CRISPR-Cas genome and epigenome engineering tools towards retinal degenerations
Kantor, A. (2022) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-kokmbbmdj
Self-citationWei, G., & Lu, Z. (2026) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-026-07195-3
Ali, R., Babar, M., Atique, M., Qammar, M., Muqaddas, & Bhuiyan, N. J. K. (2025) · Annual Methodological Archive Research Review · doi:10.63075/ycm82r67
Nano Delivery Systems for In Vivo CRISPR/Cas-Based Gene Therapy: From Vectors to Clinical Outcomes
Chen, R., Zhou, H., Wu, Q., & Gong, C. (2026) · ACS Nano · doi:10.1021/acsnano.6c12154
Thakur, S. K., Malviya, R., Chandra, P., Sridhar, S. B., Shareef, J., & Wadhwa, T. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2754253
Metadata
- Authors
- Salman, A., Kantor, A., McClements, M. E., Marfany, G., Trigueros, S., & MacLaren, R. E.
- Affiliations
- University of Oxford (GB)
- Centre for Biomedical Network Research on Rare Diseases (ES)
- Department of Genetics Microbiology and Statistics, University of Barcelona, 08007 Barcelona, Spain
- Corresponding author
- Salman, Ahmed
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-09-01
- Volume
- 14
- Issue
- 9
- Pages
- 1842
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9503525
- OpenAlex
- W4294169508
- Cited by
- 37
- References
- 192
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 8 · 2023: 10 · 2022: 2
- FWCI
- 0.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- NIHR Oxford Biomedical Research Centre
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- CRISPR-Cas, non-viral delivery, nanoparticles, retina, ocular gene therapy, gene therapy vectors, blood-retinal barrier, nanomaterials, genome editing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.